Research and development of Chinese anti-COVID-19 drugs
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
General Pharmacology, Toxicology and Pharmaceutics
Reference133 articles.
1. The proximal origin of SARS-CoV-2;Andersen;Nat Med,2020
2. Characteristics of SARS-CoV-2 and COVID-19;Hu;Nat Rev Microbiol,2021
3. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2;Monteil;Cell,2020
4. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator;Bian;Acta Pharm Sin B,2021
5. Candidate drugs against SARS-CoV-2 and COVID-19;McKee;Pharmacol Res,2020
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chinese Medicine for Treatment of COVID-19: A Review of Potential Pharmacological Components and Mechanisms;Chinese Journal of Integrative Medicine;2024-07-03
2. Identification of bioactive ingredients and potential mechanisms of flowers of Hosta Plantaginea in treating pneumonia based on network pharmacology and experimental validation;Fitoterapia;2024-07
3. GDilatedDTA: Graph dilation convolution strategy for drug target binding affinity prediction;Biomedical Signal Processing and Control;2024-06
4. Carrimycin inhibits coronavirus replication by decreasing the efficiency of programmed –1 ribosomal frameshifting through directly binding to the RNA pseudoknot of viral frameshift-stimulatory element;Acta Pharmaceutica Sinica B;2024-06
5. Bile acids and coronavirus disease 2019;Acta Pharmaceutica Sinica B;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3